Revised forecast
Fiscal year ending March 2027 · Second quarter (interim period) and full yearPrevious forecast published 14 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Revenue was revised downward because sales of gelatin for the domestic market and collagen peptide exports, among others, are expected to fall short of the initial assumptions. The forecasts for operating profit and ordinary profit were unchanged due to improved profitability and lower system-related costs, among other factors. Profit attributable to owners of the parent was revised downward because an impairment loss on fixed assets associated with the cancellation of development of the new system was recorded as an extraordinary loss, among other factors.
Impairment loss on fixed assets: ¥1.5 billion (both consolidated and non-consolidated financial statements)
| Item | Details |
|---|---|
| Net Sales | Second quarter (interim period) 21,000 / Full year 43,000 → Second quarter (interim period) Current-period actual 19,512 / Full year 41,000（Second quarter (interim period) -7.1 / Full year -4.7） |
| Operating profit | Second quarter (interim period) 2,400 / Full year 4,700 → Second quarter (interim period) Current-period actual 2,388 / Full year 4,700（Second quarter (interim period) -0.5 / Full year Not disclosed） |
| Ordinary income | Second quarter (interim period) 2,500 / Full year 4,800 → Second quarter (interim period) Current-period actual 2,546 / Full year 4,800（Second quarter (interim period) 1.9 / Full year Not disclosed） |
| Profit attributable to owners of the parent | Second quarter (interim period) 1,200 / Full year 2,400 → Second quarter (interim period) Current-period actual 235 / Full year 1,400（Second quarter (interim period) -80.4 / Full year -41.7） |
| Net income per share | Second quarter (interim period) 65.89 / Full year 131.77 → Second quarter (interim period) Current-period actual 12.91 / Full year 76.80 |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Second quarter (interim period) and full year |
| Publication date of previous forecast | 14 May 2026 |
| Previous-period results | Second quarter (interim period) Net Sales 18,499 / Operating profit 2,324 / Ordinary income 2,388 / Interim net income attributable to owners of the parent 2,214 / Interim net profit per share 121.88 / Full year Net Sales 38,048 / Operating profit 4,664 / Ordinary income 4,783 / Profit attributable to owners of the parent 3,282 / Net income per share 180.54 |
| Reason for the revision | Revenue was revised downward because sales of gelatin for the domestic market and collagen peptide exports, among others, are expected to fall short of the initial assumptions. The forecasts for operating profit and ordinary profit were unchanged due to improved profitability and lower system-related costs, among other factors. Profit attributable to owners of the parent was revised downward because an impairment loss on fixed assets associated with the cancellation of development of the new system was recorded as an extraordinary loss, among other factors. |
| Details and amount of extraordinary loss | Impairment loss on fixed assets: ¥1.5 billion (both consolidated and non-consolidated financial statements) |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales of gelatin for the domestic market and collagen peptide exports, among others, are expected to fall short of assumptions, resulting in a downward revision to the revenue forecast. The forecasts for operating profit and ordinary profit were unchanged due to improved profitability, lower expenses and a decrease in system-related costs. Profit attributable to owners of the parent was revised downward due to a ¥1.5 billion impairment loss on fixed assets associated with the cancellation of development of the new core system and other factors.